InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | 2026-03-11 | Germano Geno J | Director | Purchase | 20.0K | $1.30 | $26K | 40.0K | View ↗ | |
| 2026-03-05 | 2026-03-09 | Ellis Sean | Director | Purchase | 10.0K | $1.23 | $12K | 188.1K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| REVENUES | $42K-76.8% | $181K | $0-100.0% | $134K |
| COST OF REVENUES | $42K-75.6% | $172K | $0-100.0% | $101K |
| GROSS PROFIT | $0-100.0% | $9K | $0-100.0% | $33K |
| Research and development, net | $6.0M+33.5% | $4.5M-0.2% | $4.5M-22.9% | $5.8M |
| General and administrative | $5.5M+8.4% | $5.1M+15.0% | $4.4M-38.9% | $7.3M |
| TOTAL OPERATING EXPENSES | $11.5M+20.2% | $9.6M+7.9% | $8.9M-31.9% | $13.1M |
| OPERATING LOSS | $11.5M+20.3% | $9.6M+7.8% | $8.9M-31.7% | $13.0M |
| FINANCIAL INCOME, NET | -$90K-55.2% | -$58K-87.1% | -$31K+62.7% | -$83K |
| LOSS BEFORE INCOME TAX | $11.4M+20.1% | $9.5M+7.5% | $8.9M-31.5% | $12.9M |
| INCOME TAX EXPENSES | $0-100.0% | $14K-51.7% | $29K-78.8% | $137K |
| NET LOSS | $11.4M+19.9% | $9.5M+7.3% | $8.9M-32.0% | $13.1M |
| LOSS PER SHARE BASIC | $250+0.0% | $250-19.4% | $310-31.1% | $450 |
| LOSS PER SHARE DILUTED | $250+0.0% | $250-19.4% | $310-31.1% | $450 |
| WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE | $46.19B+22.7% | $37.65B+29.8% | $29.01B+0.7% | $28.81B |
| WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE | $46.19B+22.7% | $37.65B+29.8% | $29.01B+0.7% | $28.81B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near
Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript